Investors, Strategics & Innovators

Bio coming soon.

Dr. Myles Greenberg has more than 20 years’ experience in growing healthcare, medical technology and life sciences firms as an entrepreneur, operating executive, board member, clinician and investor. Prior to joining Alucent, he served as Chief Development Officer at IntegraMed America, a private equity backed healthcare services firm. He still serves today on the Board of Directors at Urgent Care Centers of New England, a company he co-founded.
Dr. Greenberg has spent most of his career as an early-stage venture capital investor with CHL Medical Partners, HealthInvest Equity Partners, and Pappas Ventures. Dr. Greenberg served as a board member, lead director, and in interim management roles in numerous biotech, medical device, and healthcare services firm. Eight of the companies where Dr. Greenberg played a major investor and advisory role were acquired or went public.
Dr. Greenberg began his career as a faculty physician and hospital administrator at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston. He holds a Master of Business Administration from Harvard Business School, Doctor of Medicine from Yale University School of Medicine, and a Bachelor of Applied Science from the University of Pennsylvania. He is a Diplomate of the American Board of Emergency Medicine.

Bio coming soon.

Physician passionate about impacting healthcare systems through innovation and cutting-edge technologies. Long-time health policy and patient advocate. Currently dedicated to turn artificial intelligence into actionable intelligence in surgical care at KelaHealth.

Former Senior Scientist at Boston Scientific; Ph.D. in Bioengineering from Penn State University.; Postdoc in Biomedical Engineering at the University of Minnesota; MD from Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.

Cary Vance was appointed President and CEO of PhotoniCare in May 2023, bringing over 20 years of global MedTech executive experience. Previously, he served as President & CEO of Titan Medical, Xcath Incorporated, OptiScan Biomedical, Myoscience Incorporated and Hansen Medical; strategically transforming and commercializing these businesses and markets with disruptive, enabling and game-changing novel technologies. Cary has executed on equity and debt financing strategies as an integral step to successful value creation and M&A events. Prior to his CEO role at Hansen Medical, he served in various global executive leadership roles at Teleflex, Covidien and GE HealthCare. Cary is Lean/Six Sigma Black Belt Certified, and earned both a Bachelor of Arts degree in Economics and an MBA from Marquette University.

Bio coming soon.

Bio coming soon.

Rob has spent more than two decades bringing medical device technologies to market, including proprietary orthopedic materials. He served at Tornier NV as Global Vice President, Research and Development, during which time Tornier grew from approximately $70M to $300M in annual revenues through organic growth of new products. He holds more than 30 issued or pending patents.

Introducing new medical 3D printing technology to improve the lives of people with bone defects.

I am a dedicated Sales and Marketing leader with a passion for MedTech commercialization.

Leading and growing the sales and marketing team at Ossiform. #WePrintBone

My main interests include commercialization strategy, healthcare stakeholder collaborations, and value creation and demonstration strategies.

20+ years of well-rounded experience in the Healthcare industry with a proven track record of driving revenue in Medical Devices, Biologics, and Pharmaceutical businesses ranging between <$10M - $1B+. Leadership experience and capabilities include full P&L responsibility, sales leadership/development of direct and indirect channels, capital fund raising, performance management, business development, marketing leadership, brand leadership, FDA / PMA / IDE / 510K product development, launch execution, alliance management, sales education and talent development. These diverse capabilities have successfully been applied in small, newly emerging companies and large, global organizations that are developing sales forces, launching products, developing new markets, or maximizing mature brands in highly competitive markets. Possess extensive knowledge and successful experience penetrating the acute care market by working with GPO’s, GPO subgroups, IDN’s, Hospitals, and Healthcare

“I did then what I knew how to do. Now that I know better, I do better.” – Maya Angelou

The beauty of what Maya Angelou is highlighting is people’s ability to learn and improve. I have a strong desire to learn, which is why I got my master’s degree and completed the Medical Innovation Fellowship. I have learned so many technical and soft skills working on many challenging, real-world engineering problems (water-resistant ankle foot orthotic, wearable finger force sensors, etc.) and I am excited to never stop learning.

My compass in all that I do has always been about engaging with people, from running my own swim school and teaching lessons to people of all ages, to conducting my masters research on underrepresented injuries in the wrist. Now, as Vessl's CEO, I am passionate about designing for the end user, engaging the end user early in the design process and keep their needs paramount throughout.

I am an outgoing and natural born leader and have taken many opportunities to hone my leadership skills, such as mentoring my peers during my master’s work and holding a presidential role in two undergraduate clubs, and now leading Vessl.

Bio coming soon.

Bio coming soon.

Promaxo is led by Dr. Amit Vohra who is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. Amit serves as a board member at Navaux and an advisor to Fanisko, Triocula and UnityDx.

Richard will share the story of SANA Health at the Emerging Medtech Summit and discuss partnering and investment objectives.

With an MBA in Healthcare and Entrepreneurial Studies from Wharton Business School, Hanbury went on to become the founder of Sana, a device that allows anyone to have deep relaxation and pain relief anywhere in an average of 8-10 mintues. Sana has decades of research and anecdotal data and has just complete their first internal controlled trial. 

More than a decade of experience leading cross-functional glucose sensor development teams, previously led product development of sensors and connected devices.

Mr. Liu will share the Vena Vitals story at the Emerging Medtech Summit and will discuss investment and strategic partnering opportunities. 

Ray is an executive leader in healthcare technology, with expertise in building, launching, and running products and services for both startups and multinationals. Prior to Vena Vitals, he ran product and operations for Ediom, where he created hospital decision support tools that led to the company's acquisition by Vizient, Inc. Ray also led product for Socialwellth, where he directed the development and launch of a consumer health engagement platform that was rolled out to 15.2M users, leading to the company's acquisition by Cigna. 

At Siemens, Ray developed strategies, turnaround plans, and new market entries for the healthcare, energy, and industrial business units, and at GE Healthcare, he led the global launch of patient vital sign monitoring devices from China to the rest of the world. In addition to co-founding and running Vena Vitals, Ray also serves as an advisor to MDstewardship, a telemedicine company focused on antimicrobial stewardship. Ray holds an MBA from Harvard Business School, an MS from the University of California at Berkeley, and a BS from the University of Illinois at Urbana-Champaign. 

27 years of executive leadership proficiency in both medical device start-up and multinational organizations. Specific experience in C-level general management, product development, scaling, go-to-market, and commercialization, focused on the fields of respiratory, anesthesia and critical intensive care medicine.

Notable Companies: Medtronic/Covidien, Vyaire, Boston Scientific, UCB Pharma; numerous Board Member positions

Throughout his career, Ananth has sought to improve the patient experience. He is the only medical physicist ever to win the Human Touch Award, which recognizes a passion for improving the quality of care for cancer patients within Ontario.

Ananth has a history of peer-reviewed research focused on improving image guidance for medical procedures ranging from radiation to surgical oncology techniques. His primary focus has been on making precision surgery simpler through targeted innovation and increasing access to high-quality care. Ananth is co-inventor on numerous patents and has garnered several grants for medical device innovations.

Ananth's commitment to improving the treatment process for patients inspired him to develop the magnetic tracking technology that resulted in the creation of MOLLI Surgical. Prior to co-founding the company, he was a certified medical physicist at Sunnybrook Odette Cancer Centre and clinical operations lead, brachytherapy. Under Ananth’s leadership, Sunnybrook’s brachytherapy program became one of the highest performing in the world.

Ananth completed his doctoral studies at the University of Toronto. He has held faculty appointments at Sunnybrook Research Institute, the University of Toronto, and Ryerson University.

Ash has more than 30 years of senior executive management experience in implantable devices and biotechnology. Prior to BVT, Ash held the position of Vice President Asia Pacific, the Middle East and Israel, at TransMedics Inc. Ash also held Vice President and Managing Director roles within several other major Australian and International medtech organizations such as Thoratec, St Jude Medical, Micromed, Syncardia, Ventracor, Biotronik, SulzerMedica and Telectronics. Ash has extensive experience in medical technology commercialization, general management, research and development, marketing, market entry strategies, regulatory and reimbursement across multiple geographies (USA, Asia Pacific and Europe). He is also a Fellow of the Australian Institute of Company Directors and has extensive governance experience being a Non-Executive Director on the board of ASX-listed Company DorsaVi for over 10 years.

Qualifications

BSc (E.Eng/Med Eng with Honors)

MSc (Med. Eng)

PhD (Med. Sc)

FAICD

Alan has served in senior business development and marketing positions at development stage and emerging medical technology companies for more than 25 years. He has global senior management experience enhancing investor value, including execution of successful fund raising through IPOs, private placements, and cross border M&A transactions. His experience includes work at Alira Health, EnlightenVue, Simplicity Orthopedics, ABIOMED, Implant Sciences, Kirschner Orthopedics and ACUFEX MicroSurgical.

Youssef is the CEO and one of FluidAI founders. Youssef has led the development and growth of FluidAI throughout his Nanotechnology Engineering degree, implementing its novel approaches in improving the clinical workflow for both patients and physicians. Coming from a medical family himself allowed him to live the most common challenges seen across many patient journeys. Youssef pursued his Masters in the field of implantable biochips while running FluidAI as a startup. The research work helped establish the foundation of FluidAI's first product. His focus remains on building systems and products that integrate seamlessly with existing medical products and procedures, while improving patient outcomes and growing FluidAI into a leading medical company.

Todor Jeliaskov brings over 20 years of experience solving customers’ needs and generating returns for investors and shareholders at large, complex enterprises and startup organizations across continents and various industries. Before inHEART, Todor Jeliaskov was CEO of NuVera Medical, acquired by Biosense Webster (Johnson & Johnson) in November 2020. NuVera developed the next-generation intracardiac imaging technology for cardiac interventions - 4D ICE. Todor Jeliaskov previously served as VP at GE Ultrasound - the worldwide market leader in diagnostic ultrasound. Todor Jeliaskov started his career at Siemens Medical Solutions. He holds a Ph.D. in Electrical Engineering and an MBA degree.

Adam Szaronos joined the executive leadership team in June 2020 to oversee the company’s global expansion efforts. Adam brings 15 years of industry experience in the pharmaceutical, medical device, and medical technology sectors, where he and his teams have worked on 30+ new technology launches across areas of cataract, refractive, and vitreoretinal surgery, diagnostics, and digital health. Adam is most passionate about building and leading high impact teams focused on “white-space” new ventures and opportunities. Prior to TearLab, Adam most recently served as the Head of Dry Eye Devices at Alcon, where he was responsible for launching and leading this new business unit for the organization. Over his 13 years at Alcon, he has held leadership roles in various sales, marketing, and strategy functions across their surgical and vision care businesses. Adam earned his M.B.A from MIT’s Sloan School of Management, with a focus on Innovation Leadership, and his B.S. from Indiana University’s Kelley School of Business, where he completed a double major in Marketing and Operations.

Dushyanth led the Acute Care Franchise within Dr. Reddy’s innovation business for several years. His responsibilities included the commercialization strategy of acute care products, which was the company’s highest value portfolio. He has had a proven track record in product conceptualization, invention, development, and licensing of products and devices across a number of therapeutic areas. He was responsible for the entire US branded sales and marketing organization, while also managing the corporate development and M&A function. He also held senior leadership roles across portfolio optimization, alliance management, and strategic planning.

Berk Tas serves as the Chief Executive Officer and President of SentiAR. Berk has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. Prior to joining SentiAR he led the development of a novel Trans-aortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, he played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology. Prior to that he served in various leadership roles at Sunshine Heart developing a first of its kind, heart failure therapy and at Boston Scientific developing several novel therapies and technologies focused in Cardiac Rhythm Management. He holds an MBA from the Carlson School of Business at the University of Minnesota and a BS in Electrical Engineering and Physics from the School of Engineering at St Thomas University.

Dr. Maria Artunduaga is a Colombian-born physician-scientist and inventor with 50+ prizes, publications in Nature, NEJM, PNAS, and Genetics in Medicine, and six issued patents. She left a surgical career to found Samay ("breathe deeply" in Quechua) after losing her grandmother to a COPD crisis. She has raised $3.7M in non-dilutive grants and private investment to build a chest wearable + AI-powered platform for respiratory health and management. Before Samay, Dr. Artunduaga completed postdoctoral studies in Human Genetics at Harvard Medical School, started a plastic surgery residency at The University of Chicago, and completed two master's degrees, one in Global Public Health at the University of Washington and another in Translational Medicine at University of California at Berkeley and San Francisco. She lives in Mountain View, California, with her husband, 6-month-old daughter and two pets. In her free time, she enjoys flamenco dancing, traveling the world and fostering diversity in and outside the workplace.

Bryan will share the Pristine Surgical story at the Emerging Medtech Summit and discuss partnering and fundraising updates. 

Mr. Lord works with start-ups and investors to bring new med-tech, high-tech, clean-tech, and software products to the market and to help companies scale. He has experience as an executive, entrepreneur, advisor, deal facilitator, and investor. 

Osman obtained his MD from the University of Glasgow and his MPH from Johns Hopkins. He is a Board-Certified nephrologist with a passion for Home Dialysis. He is an experienced Clinical researcher and entrepreneur who has run several businesses in the Dialysis industry including a Clinical Research company and several Dialysis Units in San Diego. He currently serves on the Palomar Health Foundation Board.

Ms. Jiang will share the details of Avisi Technologies at the Emerging Medtech Summit and be available to discuss investment and strategic partnering interests.

Rui Jing brings extensive experience in healthcare and regulation. Rui Jing gained corporate development, strategic marketing, and product management experience from working at Allergan and Sanofi, before working at JP Morgan as an equities analyst.

Rui Jing graduated cum laude from Wharton at the University of Pennsylvania with a B.S. in Economics, concentrating in Strategic Management and Finance.

Ilan, CEO and Co-founder of CAPS Medical, has over 20 years of experience in the medical device and defense industries, having held executive management positions in multiple biomedical device companies in the fields of electrophysiology, invasive cardiology, and minimally invasive implantable maxillofacial solutions. He has served in executive leadership positions at OSSIO, and Rainbow Medical portfolio companies, contributing to these companies’ continuous growth through a deep understanding of the medical device market, strategic product development, regulatory road-map building and execution, including CE and FDA compliance and successful product commercialization and revenue growth in US and European markets. Earlier, Ilan held R&D and project management positions in Unit 81, Israeli military intelligence’s elite technology unit, where during his tenure, his teams delivered numerous technologically and operationally complex projects, playing an important role in winning the top Israeli defense prizes. Ilan holds a BSc degree in mechanical engineering, an MSc in biomedical engineering, and an MBA – all received from Tel Aviv University.

Mr. Perry brings 27 years of experience in medical device start-ups including having led or contributed to multiple exits, venture financings, an IPO, 17+ medical product introductions, 20+ business development deals, and multiple regulatory approvals.

Kevin joined Lumicell as Chief Financial Officer in 2018 and currently serves as President and Chief Executive Officer. He leads an experienced team dedicated to changing the way cancer surgery is performed. Kevin brings over 25 years of global executive management experience in a variety of life science product and manufacturing companies. Prior to Lumicell he held leadership roles at ReWalk Robotics, NxStage Medical and Boston Scientific. He holds a B.S. in accounting from West Virginia University.

Prior to AccurKardia, Juan was President of the largest non-emergency medical transportation company in Puerto Rico and a reformed former investment banker.

James Carpenter has served as CEO of SurePulse Medical since its incorporation in mid-2014, having worked to secure considerable grant funding for early development and trials. He has spent 7 years working in medical device engineering and development, particularly focussed on blood flow analysis in the field of Laser Doppler Blood Flowmetry. More recently his work has been centred on high-reliability heart rate estimation. He holds a PhD in Electronic Engineering from the University of Nottingham.

Jeff O’Donnell, Jr is a healthcare entrepreneur who has merged a foundational corporate beginning with start-up agility. Jeff began his career and development at large Fortune 500 organizations. Throughout his tenure, Jeff has held almost every role in commercial organizations from Product Management to VP of Sales and Marketing. Since 2013, Jeff has helped grow and operate multiple emerging growth start-ups in the Orthopedic, Cardiology, and Digital Health spaces. He is a proud graduate of the Haub School of Business at Saint Joseph’s University, in Philadelphia.

Currently, Jeff is the President of Runway Management Corp., which oversees the direct management of the Runway Healthcare, LP portfolio companies. Jeff serves as CEO of Waypoint Orthopedics, Inc., and of Toetal Solutions, Inc.

Additionally, Jeff is a Managing Partner of MAST Labs, LLC. and sits on the boards of various healthcare companies.

Servant leader with a proven record of producing results in the U.S. and internationally for companies ranging from entrepreneurial startups to Fortune 500 companies including Abbott Laboratories, St. Jude Medical, Topera, AGA Medical, Itamar Medical, WebMD and AngioDynamics.

I have a legacy of building cohesive teams and providing strategic direction for the commercialization and early adoption of emerging therapies while maximizing existing products in highly competitive medical device, digital health and medtech markets.

My success can be demonstrated by a broad range of accomplishments that have included:

• Conceptualizing and executing commercial launch strategies for US and international markets.
• Serving in senior leadership roles during 3 different organizations’ mergers/acquisitions.
• Leading go to market efforts for private equity and venture-backed companies.
• Turning around organizations in US and the EU.
• Driving rapid revenue growth to levels that contributed to two medical device company IPOs.
• Collaborating with CTOs on development and optimization of new technology.

My experience in general management, operations, sales, marketing, logistics, client services, clinical support, new product development/launches, and new device acquisitions gives me the ability to spearhead strategic planning, communicate a company’s vision, and serve as a primary catalyst to drive growth or penetrate new markets on a domestic or global level.

The founder and CEO of Innoventric and the inventor of the company’s technology. Amir has 15 years of experience in the medical device field, mainly in structural interventional cardiology, bringing aortic, mitral and tricuspid valve projects from concept to clinical application. Amir served in some of the most exciting structural heart projects and has a broad experience in R&D, clinical affairs, regulatory affairs and business development.

Amir holds a B.Sc. in Biomedical Engineering from Ben-Gurion University and a M.Sc in Mechanical Engineering from Tel-Aviv University.

Proven Commercial Organization Leadership in Medical Devices and Pharmaceuticals - Early-stage experience and rapid-growth small company

General Manager and Marketer with consistent revenue, profit and EBITDA growth in Medical Devices, Pharmaceuticals, and Consumer Packaged Goods (CPG). From commercial strategy to market development to regulatory pathways, extensive new product development and global launch experience, including sales, marketing, and development of regulated medical devices and therapies. Leadership experience in small and large companies, from start-up to turn-around, and new acquisition integration. Known for insightful branding strategies, and strong relationships with customers and product development partners. Expertise in:

• Identifying opportunities for disruptive innovation and out-sized commercial results
• Building effective marketing and customer-facing teams that deliver results - quickly
• Building "moat-protected" market positions with strong commercial branding
• Creating long-term product strategies and roadmaps for sustainable results
• Working within both large, highly-matrixed organizations as well as bare-bone start-ups with no funding
• International market development and launch: building sales and marketing teams that deliver, Day 1
• Engaging with FDA, Health Canada, and other global regulatory authorities
• Selling to large IDNs, ACOs, and third-party payers

Mr. Goel brings 15+ years of experience in medical device software/hardware design, specializing in the development of novel imaging, visualization, and analysis systems for vascular surgery. Working closely with surgeons, he developed a keen understanding of current clinical challenges and unmet needs, leading him to invent the IOPS™ technology.

Mr. Biggins will represent Access Vascular at the Emerging Medtech Summit and will be available to discuss investment and strategic partnering objectives.

After shadowing physicians at a Boston Hospital and witnessing complications first-hand, James was compelled to design a better venous catheter. Before founding Access Vascular, James held product development, engineering, and clinical affairs roles at Ocular Therapeutix, Boston Scientific, and Medtronic, bringing over a dozen products from concept to commercialization.

James Y. Lancaster, Chief Executive Officer, is a seasoned entrepreneur and business development executive with 30 years of experience across multiple industries. He was most recently the Founder and Managing Director of the Innovate Family of Companies with client technologies including a variety of software, innovative materials, internet-of-things, robotics, autonomous vehicles, drone technologies, medical device, biological control, and waste recycling technologies. Prior to becoming an entrepreneur, he worked for Deloitte Consulting in Dallas with Fortune 500 and held other executive positions in business software and services, medical technologies, and IT solutions. 

Mr. Narrow will be a presenter at the Emerging Medtech Summit and will share the story of Sonavex and discuss investment and partnering goals.

David previously worked with multinational medical device companies to commercialize their technologies and provide long-term business strategy as a healthcare consultant at Health Advances LLC. Narrow earned his B.S. in Biomedical Engineering with Highest Distinction from the University of Rochester before receiving his Masters from Johns Hopkins University. Narrow was named 30 Under 30 in Healthcare by Forbes in 2016 and 40 Under 40 by the Baltimore Business Journal in 2017.

Dr. Gura is a nephrologist with more than 50 years of clinical and research experience. He is a worldwide expert in dialysis technology and a clinical professor at UCLA's Geffen School of Medicine.

Serial entrepreneur, Angel Investor, and Board/Advisor with a proven track record leading, growing and monetizing technology-driven companies across the full life-cycle of inception & funding to product-launch & exit. Twenty-five years of success building world-class organizations and executing "idea-to-implementation" hyper-growth strategies for FDA-regulated MedTechs, University spin-outs, Tech-company turnarounds, IoT businesses, and Disruptive Technology Innovations.

Chief Executive Officer of THINK Surgical, an orthopedic robotics and digital surgery company, committed to a new business model offering more choice to physicians and their patients.

Executive chairman and board member responsible for company strategy, financing and corporate governance.

Globally experienced medical device and healthcare executive with a reputation for achieving tangible operating results.

Transformative growth leader adept at creating vision, providing strategic direction and executing ambitious plans.

Core competencies:

Global Strategy Development & Execution • Shareholder Value Creation • Top Line Growth • Efficiencies • P&L • Business Development • Sales & Marketing Leadership • Strategic Investments • Market Innovation • Research & Development • Acquisitions & Integrations • Change Management • Turnaround Management • Team Leadership • Vision & Goal Setting • Strategic Planning • Talent Development • Mentorship • Board and Board Committee Leadership

Mr. Appelbaum has more than 25 years of life sciences & biotech experience, including business development, marketing, sales, and management. He was appointed President & CEO of Novian Health in 2005 and has led the development of an image-guided, laser ablation therapy for treating tumors. He has successfully raised over $20 million and led the development of Novian’s manufacturing operations.

Previously, Chip spent five years as Vice President of Corporate Development at Source Precision Medicine, a molecular diagnostics startup he helped found and nine years at Amgen where he managed the business development department and then led the Infergen® launch team. Prior to Amgen, he served in a technology transfer role at Argonne National Laboratory and conducted contract research at Battelle. He holds an MBA from the University of Chicago and an S.M. in Chemical Engineering from MIT.

Peter Vranes is a Chemical Engineer and serial entrepreneur. Peter is the co-founder of Nutromics, an Australian MedTech company revolutionising healthcare through continuous real time molecular monitoring. The company’s innovative Smart Patch biosensor platform will solve some of the biggest healthcare challenges we face today in the fields of chronic disease prevention, chronic disease management, acute diseases and Therapeutic Drug Monitoring. 

Prior to Nutromics, Peter founded Biocore Technologies and lead the team with the development and commercialisation of several natural cosmeceutical skincare brands that were distributed in 1,500 retailers throughout Australia. The company was successfully sold in 2013.

Bio coming soon.

High energy CEO, Sales, Marketing, & Business Development leader with over twelve years as an International expatriate.

Strong track record of delivering results in both blue chip and early-stage companies. Expert at developing new markets, driving growth, executing turnarounds, and creating winning cultures.

History of driving rapid market penetration for new medical device technology, through: 1) field sales effectiveness, 2) strong customer development, 3) clinical economic arguments, 4) targeted physician & referral pathway marketing

Specialties:
- Sales, Marketing, Strategy, New Business Development
- International Growth Execution, Europe, Asia, Americas
- Sales & Field Force Effectiveness
- Physician Adoption, New Market Development
- Marketing to Physicians & Direct-to-Patients
- General Management
- Early-Stage Company Growth, Turnarounds
- Global Product Commercialization
- R&D Product Development & Manufacturing
- Organization Design to Drive P&L Growth

Co-founder & CEO, Claude has more than twenty years of global experience in the Health Care industry in product & market development in pharmaceuticals & vaccines (Merck & Novartis). With extensive sales & marketing experience at the global and market level, including product launch, Claude led HPV vaccine blockbuster Gardasil regulatory, market development & commercial launch efforts. He also developed MenB vaccine, Bexsero, scientific platform, product profile & market development leading global marketing efforts through EMEA filing.

Chief Executive Officer at Cognoa, Inc. which is using Artificial Intelligence to diagnose & treat neurodevelopmental and neurobehavioral disorders early to help children reach the fullest potential. Former Division Chief of Pediatric Neurology & Medical Informaticist at Children's Health of Orange County (CHOC). Associate Clinical Professor of Pediatrics at University of California - Irvine, and Affiliate Professor at Chapman University Dale E. and Sarah Ann Fowler School of Engineering. Innovator, inventor, and advisor of medtech achieving FDA Breakthrough designation x3 and de novo market authorization for first of its kind autism spectrum disorders diagnostic.

Dr. Margaret Kalmeta is a Doctor of Dental Surgery with extensive training in oral surgery.  She built and successfully exited several startup practices, subsequently went on to develop and patent novel tissue and bone growth technologies. Learning that daily amputations measured in the hundreds because of poor technologies, Dr. Kalmeta transferred her oral surgery wound healing technology to the wound care industry and founded Rapid Nexus, Inc in order to address this critical unmet patient need.  

Bio coming soon.

Richard has 20+ years’ experience of building international businesses and has throughout his career sought opportunities for positive market disruption through technological application.

It was this desire that led him to co-found FundamentalVR to help address an age-old problem for the medical market; how to create safe, realistic, measurable spaces to learn and develop skills.

In his role as CEO Richard is responsible for building a world class team of medical, learning and technologist who together can realise the company’s ambition of creating the world’s first global, haptically enabled, low cost ‘flight simulator for surgeons’.

Dedicated to finding new and better treatment options for patients that have challenging cardiovascular problems. My efforts have focused on developing medical devices and technologies that impact treatment of heart rhythm and other important health problems. My inclination is to work on projects where new therapeutic technologies are evolving from the preclinical into the clinical phase while maintaining a presence on the front line of clinical cardiology.

Gregory Fischer has spent his career developing innovative technologies for image-guided surgical interventions. He is a pioneer in MRI-compatible surgical robotics capable of utilizing real-time images from inside the body to guide precision robot-assisted interventions. Dr. Fischer is a Founder of AiM Medical Robotics, a company leveraging technology from his team's research to revolutionize the neurosurgery experience. Dr. Fischer is also the William Smith Dean’s Professor of Robotics Engineering at Worcester Polytechnic Institute (WPI) and PI of the Automation and Interventional Medicine Robotics Research Laboratory (AIM Lab) where his research focuses on medical robotics, specifically the use of real-time feedback to guide surgical procedures. He is Director of the PracticePoint Research and Development Center for Healthcare Cyber-physical Systems, a state-supported Medtech accelerator with advanced point-of-practice clinical testing facilities including an OR and 3T MRI suite dedicated to research and product development.

David joins the executive team with decades of extensive experience in medical device, imaging, and healthcare technology innovation. He is a passionate leader with a demonstrated track record of leading cross-functional teams from early clinical development to M&A through global commercialization in 60 different markets and geographies. He comes on board at a pivotal time in the company’s journey, bringing the wealth of knowledge and expertise necessary to take Body Vision’s business to the next level. David holds an MS in Business Administration and Management from Troy University and a BA in Psychology from The Citadel.

With key experience working in start-ups in the design and development of structural heart implants including transcatheter replacement heart valves (aortic, mitral, tricuspid), working across Canada, the US and Europe for the past 13 years, I am deeply inspired by building, growing and supporting teams while developing elegant solutions to improve patient's treatment options, quality of life and care.

Gordie is a C-level executive with management and marketing expertise in emerging healthcare companies. His previous experience includes leading ZELTIQ Aesthetics through a private funding round and IPO. He’s served in executive positions at the following companies: Angel Medical Systems, Inc., Atlantic Therapeutics, R2 Technologies, REVA Medical, Systagenix, Critikon, Inc., and A Company Orthodontics.

His early professional experience includes marketing roles at The Gillette Company, Reebok, LA Gear and President and COO of Voit Sports. Nye is a graduate of Dartmouth College and has an MBA from Dartmouth’s Amos Tuck School of Business.

Mr. Richard Hughen is a high impact executive leader, business builder with start-up, small-cap, and fortune 100 experience, innovative thinker and creative problem solver with expertise in building shareholder value, milestone achievement with unrelenting focus, leading complex, cross-functional teams, marketing strategy and business development, product development and commercialization, trial, regulatory and reimbursement strategy, international market development and launch, sales - management and operations, intellectual property and licensing, fund raising - equity and debt, licensing and intellectual property.

I am passionate about impacting global health by leveraging my medical device and international experience to improve access, efficacy, efficiency and affordability. I believe this all starts with meaningful communication: understanding the needs and priorities of patients, practitioners, payers, governments, device creators and distributors is key to creating targeted solutions with lasting impact and financial sustainability. In addition to being an entrepreneur, I also enjoy empowering other entrepreneurs.

Ms. Leah Brownlee joined our company in her current roles in October 2020. She currently serves as board chair of Switch Automation (US), Inc. and her previous positions include of counsel in the global corporate department at Squire Patton Boggs (US) LLP, a top-20 global law firm and executive vice president of compliance and operations at Cleveland Biolabs (NASDAQ: CBLI).

Bio coming soon.

Bio coming soon.

Founder/& CEO - 40+ year life science and technology leader with product development, intellectual property, and manufacturing experience.

Ms. Farrar has 40 years of experience as an attorney representing companies in the medical device and pharmaceutical fields. She has more than 25 years of experience in strategic IP planning and working in local start-up companies. In 2008 she founded Catheter Connections, Inc., a catheter infection control company. Catheter Connections changed the standard of care for infusion therapy and was successfully sold to Merit Medical in 2017. Vicki took the company from inception to sale, along the way developing and commercializing numerous products, completing successful clinical trials, qualifying for GPO contracts, obtaining FDA and CFDA (China) clearance, and a CE Mark, as well as establishing a robust patent portfolio with all patents upheld, and an infringer enjoined. Prior to Catheter Connections, she served as VP of Regulatory and Intellectual Property at Q Therapeutics, Inc., in Salt Lake City; and previously served as Acting CEO and Vice President of Legal, Intellectual Property and Regulatory Affairs at Cognetix, Inc. in Salt Lake City, developing CNS products that required delivery through an intrathecal medical device. Ms. Farrar began her career at the law firm Covington & Burling in Washington, D.C., specializing in medical devices and food and drug law. She has been a partner at several large leading law firms, the most recent being Morrison & Foerster in San Francisco. She is responsible for establishing the strategic position of the Company and overseeing its operations.

Bio coming soon.

Dr. Robert Masson, M.D., is an internationally recognized private practice neurosurgeon, with vast experience in cerebrovascular and skull base surgery. He ultimately, in 1999, dedicated his 35 year neurosurgical career to minimally invasive spine surgery. Always innovating and pushing his limits, he is the Founder and CEO of eXpanded eXistence™, an artificial intelligence enhanced software company backed by mixed reality and machine learning, focused on surgical logistics and performance.

He has developed spine implants, technology and procedures, focusing on least invasive surgery and maximum functional recovery. He has served on advisory boards for microsurgical systems, stem cell research, radiological software, orthobiologics and sports injury treatment & prevention. In addition, he has developed, educated ,and influenced products for groups such as Sofamor Danek, Synthes, Depuy Synthes Spine, a Johnson and Johnson Company, Centinel Spine and Biedermann Motech.

20 plus years of work as a Pediatric Urologist and partner in a successful Pediatric Urology practice.

Extensive academic experience in Pediatric Urology (2018 President of the American Association of Pediatric Urology) and Secretary Treasurer of the AAP Section on Urology. Focus on linking cutting edge medical solutions and disruptive digital technology.

Founded two recent Urology medical device companies, Urospeed and Uronexus, parent company of DriQHealth. Co-Founder Women's and Children's Health Alliance (Vice President/ Chief Clinical Integration Officer)

Executive Healthcare leader with 20+ years of successful experience building businesses, differentiated products, and services that manage healthcare costs and improve patient outcomes.

I have launched three companies that provide products and services for cancer patients and their loved ones. I move companies from ideation to commercialization by bringing together top talent and subject matter experts to build differentiated patient experiences. I hold two patents and have formed a strategic collaboration with Mayo Clinic to build an implantable medical device company. I have led a clinical trial funded by the National Cancer Institute. I coached 400+ cancer patients empowering them through physical activity and nutrition.

My clients come from many industries: startups, MedTech, healthcare, medical devices, oncology, pharmaceutical manufacturing, digital health, remote patient monitoring, tele-coaching, and health and wellness. Clients tell me that I am inventive, a strong communicator (written and verbal), a collaborative and transformational leader, and passionate about improving the well-being of others.

35 years MedTech experience with startups in Operational, Consultive, Director roles. BSME/MSME. Director, MPR; Founder LifeLine Medical.

Charlie is passionate about using really small things to solve big problems. This fascination began in school; during undergrad, he helped build a microfluidic pump for an implantable therapeutic for glaucoma. During his master's, he helped form a team that developed micro solutions, which led to the formation of three companies (MY01, Stathera and Nxtsens), all of which are growing today.

Dr. Wilson is the founder and Chief Executive Officer at Egg Medical, and a practicing Interventional Cardiologist at the University of Minnesota, where he has been on staff since 1986.

He was the Director of the Cardiac Cath Lab from 1988-2004 and served as Chief of Cardiology from 2008-2013.

Dr. Wilson has a passion for advancing the Science of Interventional Cardiology and has been active in research and Product Development for many years.

Before starting Egg Medical, Dr. Wilson was the catalyst behind ACIST Medical. 

As the CEO of Advanced Scanners, I lead a visionary and strategic team that is transforming the medical device industry with cutting-edge robotics and digital surgery solutions. With over 15 years of experience in this field, I have a deep understanding of the market needs, challenges, and opportunities for innovation and growth.

One of my proudest achievements was leading a cross-functional team at Johnson & Johnson to achieve the first in human clinical use of an orthopedic robotic assisted device, a crucial priority for the company. I also expanded this initiative to build a comprehensive capital framework for robotic assisted devices and other enabling technologies. My mission is to leverage my expertise and passion for technology commercialization, product launch, and go-to-market strategy to create value for patients, providers, and partners.

Medical Device and Biosurgery executive leader with over 25 years of consistently successful experience at pre-commercial and commercial stages companies. Success in the medical device, orthobiologics, and biomaterials industries with technologies in the orthopedic, spine, neurosurgery, sports medicine, interventional radiology markets. Extensive team-building, executive management, strategy development, sales and marketing management, strategic partnership development, distribution channel development, Board management, start-up, turn around, and fund raising (over $85M) experience.

I am a former electrical/computer engineer and management consultant. I turned to entrepreneurship to solve serious problems in health care. My company's mission is to transform the way neurological conditions are recognized, managed and treated. We focus on putting the customer first, creating products that deliver exceptional buyer utility at an accessible price and building a solid business. Our game changing EEG headset and platform is available for purchase by health care facilities in the US.

Entrepreneurial MedTech leader with a record of scaling businesses, large and small. Board Chair. Keen ability to swiftly understand a business, identify needs and opportunities, apply analytics, and steer organizations in strategy implementation. Currently applying broad expertise to steer small & mid-size companies and investors - deeply involved in Go to Market, Fund-raising, IP, M&A, KOLs, Branding, and US market entry.

Full spectrum of deal expertise. End-to-end business acumen. “5-tool player.” Can galvanize cross-functional teams, partner with clinicians and inventors, and win market access. A connector and change agent who gets stuff done.

Besides consulting work, curated strategic advisory positions, indexed toward digital: Augmented Reality (OnPoint), Enterprise SaaS Sales Targeting (AcuityMD), and Cloud-based Prior Authorizations (Voluware). Most recently, appointed the Executive Chair of an Israeli biosurgery company (Nurami).

Bio coming soon.

Bio coming soon.

Bio comming soon.

Personal Work Interests - Small-Mid size growth companies with equity possibilities. I thrive in opportunities where I can wear many hats, learn, mentor, and contribute in a variety of ways. My selling skills, real world experience and networks are my biggest asset, especially when building new and emerging business opportunities. My strategies are centralized around building lasting partnerships based on strong science and an ability to quickly identify business opportunities. Examples include building scalable sales and marketing (commercial) infrastructure for young business units, building physician's office "revenue"​ models, consulting to build and proctor office based procedures, global contracting to bring YOY growth with big MedTech, and being the most dependable resource for my customers (show up, clinically & financially sound, knowledgeable of local & industry issues, do what you promise). "Bringing tremendous value to everyone around me with a contagious energy that makes it memorable."

I am an entrepreneur and business leader with a passion for guiding companies to achieve extraordinary results.

Over the course of my career I have built and led many teams in many environments, including start-ups, mid-sized privately held companies as well as large, publicly traded companies. What I am most passionate about is to teach, coach and guide people as well as companies towards the best they can be.

I have achieved great success in various leadership positions covering many functional business areas, including general management, product management, sales management, client management and operational management. I am very fortunate to have been part of six acquisitions, which taught me a great deal about motivation, flexibility and change management.

Biomedical engineer with a training emphasis in biomedical optics. Currently involved in medical device development & committed to translating biomedical technologies from lab to marketplace so patients can benefit.

Trauma and Acute Care Surgeon. Stanford Biodesign Alum. Founding CEO of Watershed Therapeutics. I probably take Halloween costumes too far.

As the Founder and CEO of Portal Instruments, Patrick Anquetil, Ph.D., MBA, leads a team of engineers, scientists, and business professionals who are developing a connected needle-free drug delivery device that improves the patient experience and adherence of injectable therapies. With over 15 years of experience in the medtech and biotech industries, Patrick has a passion for creating innovative solutions that address unmet medical needs and enhance patient outcomes.

Patrick has successfully established strategic partnerships with leading pharmaceutical companies, such as Takeda, LEO Pharma, and Sanofi, to launch combination products with Portal's needle-free technology. He has also raised over $60 million in venture capital and non-dilutive funding to support Portal's growth and development. Prior to founding Portal, Patrick co-founded SynapDx, an autism diagnostic company, and Aretais, a blood glucose monitoring venture. He also worked as a science and nanotechnology equity research analyst at Susquehanna International Group. Patrick holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard Business School, and a master's degree from ETH Zurich and the University of Tokyo. He has published his scientific work in peer-reviewed journals and mainstream media, and has been featured in MIT Technology Review, Wired Magazine, PBS, and CNBC.

My professional passions include innovating and commercializing healthcare technologies that can improve patients’ quality of life, forming and supporting talented teams so they can reach their highest potential as individuals and as a group.

I am an electronics engineer with a Ph.D. in Biomedical Engineering from Dalhousie University. I am additionally trained in the commercialization of medical devices with several years of experience, and have several issued and pending patents. I continue to draw on my background in engineering, my knowledge of breathing mechanics and entrepreneurial spirit to successfully develop our lead technology, cMAP™.

As the CEO at NovaResp, I have led our team to pioneering the very first use of AI on Positive Airway Pressure (PAP) therapy in obstructive sleep apnea (OSA) patients. The goal of this technology is to help OSA patients like my father have a more comfortable experience with their CPAP, and higher adherence to therapy.

Currently working for Orchestra BioMed, a therapeutic device company focused on the development and commercialization of high impact, data-driven solutions to address high value unmet medical needs.

A dynamic and driven clinical entrepreneur, an ISO 13485 MDSAP certified auditor, an executive professional with a Six Sigma Black Belt and a broad base of health care sector knowledge; deep expertise in strategic planning, operational performance improvement, performance management, information technology, and detailed business modeling. Excellent leadership and business development skills developed through team leadership, client relationship management, and business development. Leadership experience in design, change and risk management, establishment, and implementation. Skilled at resolving difficult client issues as well as developing standardization and quality improvement methods. Active liaison between SMEs and healthcare professionals for medical research. Excellent results in acquiring new clients and renewing existing programs.

Extensive leadership experience in medical diagnostic laboratories, as well as method development through close collaboration with the pharmaceutical, biotechnology industries, and contract research organizations. Extensive experience in building teams, project management (PMP), data management, quality assurance, and business development across all phases of clinical trial operations.

Strong ability to perform market analysis and bring disparate information together for the development of a cohesive business/strategic plan, adaptability to and promote change for market/competitive advantage, attention to detail in procedure implementation for efficient business unit management.

Bio coming soon.

Bio coming soon.

Dr. Karen Cross MD, PhD, FRCSC is a Plastic and Reconstructive Surgeon, a Scientist, and the Co-Founder and CEO of a startup health technology company called MIMOSA Diagnostics. She performs basic science and clinical translation research developing non-invasive optical technologies to assess skin physiology. Her research aims are to bring innovative technology from the bench to the bedside.

Dr. Cross has won several National and International awards related to her research such as the Wound Healing Society Young Investigator Award, Trauma Association of Canada Research Award, and Best Clinical Research from the Canadian Society of Plastic Surgeons. She has been recognized for her excellence in as a teacher, her collegiality, generosity, mentorship and humanitarianism by receiving the Dr. Hugh Thompson Humanitarian Award and the Leo Mahoney Teaching Award. Dr. Cross most recently received the 2018 Roscoe Reid Graham Scholarship in Surgical Science.

Dr. John H. Wong is an associate professor in the Departments of Clinical Neurosciences and Radiology at the Cumming School of Medicine. He serves as Director of Cerebrovascular and Endovascular Neurosurgery and maintains an active clinical practice dedicated to treating brain aneurysms and stroke. Dr. Wong received his medical education and neurosurgical training at the University of Alberta. After a one-year fellowship in neurovascular surgery at Yale University and further two-year specialization in interventional neuroradiology in New York City, he was recruited to Calgary in 2001. Since then, he has helped develop one of the most collaborative and productive neurovascular and stroke units in North America with colleagues in neurology, radiology, and neurosurgery. Dr. Wong has co-authored numerous peer-reviewed manuscripts and has served on several grant review panels including for the Canadian Institute of Health Research, and the National Institutes of Health in the U.S. He has held numerous local and national leadership roles including the former president of the Alberta Neurosurgical Society for over a decade, past Division Head of Neurosurgery at the University of Calgary, and is the current Vice President of the Canadian Neurosurgical Society. Dr. Wong received his MBA from the Wharton Executive MBA program in San Francisco. He is also co-founder and CEO of Fluid Biomed Inc., a venture-backed medical device startup company that is commercializing innovative brain stent technology.

Bio coming soon.

Graduated from University of Waterloo with a Bachelor of Applied Science (B.A.Sc.) focused in Mechanical Engineering with an Entrepreneurship Option. Michael co-founded Vena Medical during the final year of his undergraduate degree and went full-time immediately after graduating. Attended TMCx Accelerator and Y Combinator in the year following. Published author in the Journal of Neuro-Interventional Surgery and the American Journal of Neuroradiology, Inventor on a granted patent and winner of numerous awards related to business and entrepreneurship.

Executive and entrepreneur with >15 years of experience in innovative product development.

Design thinker with a demonstrated history of working in the information technology and consulting industry. Engineering Doctorate who has published papers related to metal additive manufacturing materials in the aerospace industry.

Entrepreneur with Research Background, developing class II and III medical devices to restore and improve (augment) organ function using minimally-invasive Neuromodulation.

EXPERIENCE:
• Leadership by Value, Principles, and Data. No dogma.
• Startup (Neuronoff, Oculeve) and Big Corp (Allergan, Boston Scientific).
• Conceived and developed implantable & topical neuromodulation devices.
• Extensive Clinical (incl. FDA pivotal) and Pre-Clinical experience, designing IRB / IACUC cleared protocols & executing studies. Designed or actively cut in 50+ acute and chronic surgeries.
• 59 GRANTED Patents.
• Lead inventor on ~136 out of ~194 patent applications. To date only 4 dropped ones.

RESPONSIBILITIES
• Ran MoA studies for Oculeve/Allergan TrueTear. Conveyed Value to Clin & Marketing.
• Designed and/or executed 10 Clinical Studies in 5 countries world-wide. Multilingual.
• Defined new Clinical Label by optimizing Neuromod Therapy, doubling Market Value.
• Co-Development of regulatory pathway, reimbursement strategy, and Marketing / PR pitches.
• Headed the Pre-Clinical for Oculeve. Designed & executed studies to support IRB clearance.
• Co-Designed a new QA/QMS prior to US clinical studies - ISO 13485, CE, FDA 510(k) De-Novo.
• Trained clinicians and their staff on novel neuromodulation devices and clinical data acquisition.

Jay is an experienced entrepreneur and executive in the life-science and pharmaceutical industries. Jay started his career at Bell Labs and was an executive at Cytokinetics (CYTK). He co-founded Praelux (acquired by Amersham/GE) and Vedere Bio (acquired by Novartis). He earned his PhD in Chemistry from Cornell University.

I am curious, and ambitious, and have a great interest in abstract thinking which has led me into many aspects of fine art, design, and objectively analyzing & solving problems. I'm passionate about disruptive, life-changing ideas & enabling individuals to be empowered. This led me to form Purcell, a MedTech company working on smart drug delivery for respiratory diseases.

Bio coming soon.

As Chief Commercial Officer, Scott leads our Sales, Marketing and Customer Success organizations while executing our commercial strategy for growth. Scott has over 25 years of experience in the healthcare and technology industries, leading commercial and operational teams.

Scott was previously the Chief Commercial Officer of Hyperfine (HYPR), developer of a bedside neurological MRI platform, where he led the development of their commercial strategy and supported the company’s IPO in 2022. In addition, he built a global commercial business throughout North America, Europe and APAC for Rapid Micro Biosystems (RPID), the developer of the Growth Direct System, which also led to a successful IPO in 2021. Scott also spent seven years at Intuitive Surgical as a VP of Sales, where he grew revenues in excess of $200 million annually.

Scott has a bachelor’s degree in business from the University of Florida and a master’s in business from the University of Miami. He has also successfully completed several courses from Harvard’s Executive Education Programs.

Over 20 years experience in managing and shaping organizations operating in the medical field, covering general commodities to highly sophisticated medical devices. Experienced in government relations and healthcare systems in general. Global experience, including LA, US, Asia and Europe.

Multilingual, international executive with 25 years of general management, sales and marketing experience in healthcare industries. Proven experience in establishing new businesses. Entrepreneurial and strategic attitude towards identifying and exploiting opportunities and strong leadership in implementing value driven sales, marketing and cost optimization plans. Good track record in the development and launch of new products, exploring new businesses, business models and setting up multiple channels of distribution. Strong strategic mindset and drive to accelerate growth and promote organizational change. Customer oriented decision maker, recognized for achieving results through a strong commitment to creating win-win situations and for building and developing action oriented management teams. Strong and effective leader in coordinating projects across all functions, including engineering, R&D, clinical, regulatory and finance among many others. Experienced in negotiating with high ranked government officials and c-suite as well as in negotiating mergers and acquisitions. Start up, small/medium (PME) enterprise coach and mentor.

Leading the team aiming to bring to market the solution to end the chronic wound epidemic. This devastating condition affects the elderly and those who suffer from comorbidities such as diabetes and vascular disease. Many patients with chronic wounds not only bear the physical pain of their medical condition, but also are often isolated and sequestered to their beds due to off-loading protocols. Their lives are severely disrupted and patients often spend hundreds of dollars a month out of their own pocket to cover materials needed to care for their wounds. The psychological pain and fear of amputation are the silent companions of their suffering.

The statistics point to injustices as African-American patients receive amputations at twice the rate of their white counterparts. For patients with vascular disease and chronic wounds, their 5-year mortality rate rivals the five-year mortality rates of cancer patients. Yet, because chronic wounds are not a branded disease and receive little fan fair, few research dollars flow to solve this crisis that is at epidemic levels.

Previously a founding member of Pearl Capital Advisors LLC—an award-winning investment management firm specializing in volatility-based investments where, as CIO, I led investment research, risk management, and marketing efforts for Pearl’s investment strategies.

With more than 20 years’ experience of commercial and executive leadership across medical device and medical technology companies, Matt has been hugely successful in launching disruptive technologies on a global scale throughout his career. Having previously held senior leadership positions within Proximie, Molnlycke Healthcare and CR Bard, he joined IQ Endoscopes in October 2020 bringing his extensive medical device, product development, regulation and commercialisation knowledge to the team.

With over 35 years’ experience in the engineering and materials industries and a track record of delivering fast business growth in a diverse range of start-ups, Phil is playing a key role in shaping 4D Medicine’s strategy and driving the business forward. Previous start-up roles include CEO at Interface Polymers, a polymer additive spin-out from the University of Warwick and Managing Director at a precision instrument spin-out from Cranfield University, majority owned by a FTSE 100 company. Between those appointments, Phil enjoyed a total of 12 years working as an independent consultant and a business development specialist with Warwick Ventures. Phil initially trained as an Engineering Technician in the aerospace instrumentation sector and became a Chartered Engineer in the late 90’s. Throughout his career, Phil has been excited by innovation and the satisfaction of working closely with customers to disrupt markets that are ready for change. Phil has an MBA (with distinction) from Warwick Business School, a BSc Hons in Materials Science and Technology from Brunel University and a Higher National Certificate in Mechanical and Production Engineering.

Dr. Kirschman is an entrepreneur and neurosurgeon with extensive experience in medical device development and corporate leadership. He is an organization builder with expertise in executive operations, public and private business finance, product development, regulatory affairs, sales distribution, marketing, and exit transactions. Holds over 80 issued patents for a wide range of medical devices. He previously founded X-spine Systems, a global spinal implant company (now Xtant Medical), and Orthophor, a global manufacturer of surgical irrigation products (now part of BD).

General Partner with Pitango Venture Capital’s life sciences team; Director of Business Development and Marketing at Medtronic Ventor Technologies; Corporate Development, Marketing and Market Development at Medtronic, Inc. in the US; VP of Medical Affairs at Rhythmia Medical; MD from the Hebrew University of Jerusalem, MBA from Harvard Business School.

Over the last decade, Doug has worked to shape the role that robotics will play in the future of medicine.  He currently serves as CEO of Method AI, a company he co-founded with the Cleveland Clinic to improve outcomes for robotic-assisted surgery.  Method AI aims to unlock the full value of surgical robotics through computer vision and automation, and they are starting where they can have the biggest impact for patients – surgical oncology.  

Prior to Method AI, Doug served as COO for Corindus Vascular Robotics.  In 2018, his team achieved the world’s first remote robotic interventional heart procedure – completed by an offsite physician located more than 20 miles from the patient.  They followed that achievement with the first in-human robotic neurovascular intervention in 2019.  The work of Doug and his team was featured in the 2020 documentary, Speed of Thought, a film following the first wave of 5G innovators in healthcare, public safety, and education.

Brian Stewart is the founder and Chief Executive Officer of Tally Surgical, Inc. Prior to founding Tally, Brian was the Managing Member of Innovo Ventures, a healthcare focused investment firm. Previously, Mr. Stewart was the General Manager of Patient Safety at Stryker where he was responsible for the integration of Stryker’s acquisition of Patient Safety Technologies (OTC:PSTX) and the overall operations of that business including the SurgiCount Safety-Sponge™ System retained sponge prevention solution. Prior to Stryker, Brian was the Chief Executive Officer of Patient Safety Technologies where he drove the growth of SurgiCount and the ultimate exit of that company to Stryker. After being appointed as CEO of Patient Safety Technologies, Mr. Stewart led a successful restructuring of the company’s board of directors and management team and drove an operational turnaround which resulted in considerable growth in market penetration, reported revenues, profitability and significant shareholder value creation. During his tenure as CEO, Patient Safety Technologies achieved 850%+ growth in its customer base, successfully expanded into 6 of the top 10 U.S. News and World Report Best Hospitals Honor Roll recipients and added numerous IDN wide adoptions including the largest hospital system in the U.S. Mr. Stewart was the co-founder and CEO of SurgiCount Medical and co-inventor of the marketing leading surgical sponge counting technology, the SurgiCount Safety-Sponge™ System. Additionally, Brian has over 10 years of investment and investment banking experience at Credit Suisse, CIBC and Donaldson, Lufkin and Jenrette.

Jennifer is a healthcare entrepreneur and investor. Most recently, she was the co-founder/CEO of Explorer Surgical, which sold to GHX in 2021.

Marcin joined the company in June 2022 as CEO to take it into a new phase. He brings a vast industrial and business experience in electrophysiology. He is also a Director on the board of several companies in this space.

Bio coming soon.

Bio coming soon.

Deanne McCarthy is founder and CEO of Swiftsure Innovations, bringing her experiences as a critical care nurse to develop medical a device geared toward improving the standard of oral hygiene in intensive care. Prior to completing her BN, Deanne completed a BBA from Memorial University of Newfoundland. Deanne is passionate about providing Registered Nurses with the resources they need to do their jobs effectively and is equally enthusiastic about improving outcomes for patients and reducing hospital costs.

Dr. Chris Springate has over 25 years of experience as a leader in the development of medical devices, combination products and drugs at preclinical and early clinical stage medical device companies. He engaged in the development of several successful products including the Taxus® Stent with sales of greater than USD 1 billion annually; built leadership teams including corporate, scientific and clinical boards; co-led ARC in acquiring greater than USD 30 million of equity and licensing financing; and is an inventor of several patent families that protect ARC’s products. Dr. Springate served as a hospital and community pharmacist for 7 years. He holds BSc (Pharm) and PhD (Pharm) degrees and is a Registered Pharmacist.

Adam Choe co-founded Veyond Metaverse in 2021. As the CEO, he defined the Veyond Metaverse vision and strategy, contributed to core values, and has led the company since its inception. Prior to Veyond Metaverse, Adam was CEO of two successful healthcare companies, Immunostics and NanoEnTek USA, where he commercialized products globally and defined the company's growth areas. Adam was the first employee at Johnson and Johnson Lifescan Korea, where he served as a founding Managing Director. There he developed the core brand and drove strategy and execution of commercial functions. Adam successfully served as a vice president of global health management at Alere (Now Abbott).  Adam received an MBA in marketing and strategy from Carnegie Mellon University and a BA in Biology from the University of Texas at Austin.

Bio coming soon.

Bio coming soon.

Bio coming soon.

A technology commercialization expert with over 30 years’ experience in the high-tech world of imaging, holding past roles as a CTO at Autodesk Inc and Co-Founder of Calgary Scientific.

Brian Thornes is a former orthopaedic surgeon with 17 years of clinical experience, predominantly specialising in trauma. Brian is a serial inventor of medical devices, most notably the TIGHTROPE®, which is licenced to Arthrex Inc, FL. Brian has overseen the development the X-BOLT® product portfolio and their validation in large multi-centre clinical trials.

Brian has a medical degree from Trinity College Dublin, a Masters in Surgery, Fellowship of the Royal College of Surgeons in Ireland and an MBA. Over the past decade, Brian has served on a number of Boards, including Clontarf Orthopaedic Hospital, The King’s Hospital School, and the Higher Education Authority of Ireland.

Brian is a keen golfer at Portmarnock Golf Club, and in the summer enjoys playing cricket at Malahide Cricket Club.

Finbar is responsible for leading, developing VERSONO’s short and long-term strategy and the overall management of the company’s operations. His role also involves developing and communicating VERSONO’s vision and mission with its stakeholders, customers, board of directors and government agencies. Finbar has over 20 years of executive and leadership experience within the Medical Device Industry and has worked with CR Bard, Medtronic, GTI, Lake Region/Integer, Arc Devices, in product development, strategic R&D and manufacturing operations.

Finbar has also contributed on a pro bono basis to initiatives in IBEC’s MedTech Ireland, the IRDG, the American Chamber of Commerce Ireland and Engineers Ireland. A chartered engineer, Finbar holds PhD, MBA and BSc degrees and is a BioInnovate fellow.

Mr. Ofer Halbreich serves as Chief Executive Officer at CardiaCare. He has over 25 years of diverse professional and leadership experience including business development, global operations, strategic partnerships. Prior to CardiaCare Mr. Halbreich served as Vice President of Commercial and Corporate Development of MeMed Diagnostics Ltd. Before joining MeMed's team, Mr. Halbreich led the global operations activity of MediaMind Technologies Inc., and following its purchase by Digital Generation Inc. (Nasdaq: DGIT), he led the international operations integration process of the companies. Before that, Mr. Halbreich was the COO of Neuronix Medical, an innovative medical device company in the Alzheimer's disease treatment field. Mr. Halbreich also served as a commercial lawyer for some of Israel's most prominent law firms, handling large-scale commercial activities including M&A, joint ventures, licensing, and investment agreements. Mr. Halbreich holds an LLB from the Hebrew University of Jerusalem and an MBA (Finance) from the Interdisciplinary Center in Herzliya.

Bio coming soon.

Bio coming soon.

Proactive and engaging leader with expertise in advanced strategy development and implementation driving outstanding corporate growth. Over 25 years of senior level business acumen gained through key executive positions with leading large cap to venture stage startups within the life sciences and medical technology sectors. Experience in organization-building geared to achieve near and long term milestones both in domestic and international settings. Ability to deliver significant transformation and growth in financial performance, product development, investor fundraising, capital restructuring, P&L management, and strategic planning. Recognized successes in the distressed business turnaround process. Key achievements included:

As Public Company COO:

• Extensive background in P&L management; restructured world-wide commercial operation while achieving Wall Street revenue target of $6M, while producing all-time best quarterly revenue performances overall and in high-growth China market; successfully gained entry into the $1B molecular blood typing market by partnering with a prestigious U.S. independent blood bank. 

As CEO:

• Rebuilt organization around re-focused value proposition in medical oncology while restructuring Board and raising new capital; generated key large CAP pharma partnerships based on compelling milestones to support transition through court process; arranged Series B financing with credible investors following court approved sale. 

As VP of Global Marketing:

• Delivered and implemented new marketing strategies through market focused tactics and tools, along with overall product and market positioning for large cap industry leader supporting growing revenue results over a two-year period (up to 16%) along with operating income above 20% on total product revenues exceeding $400M; key driver was geographic expansion through key xUS studies, KOLs, and tender strategies. 

Bio coming soon.

Mr. Altman will share the story of CorInnova at the Emerging Medtech Summit and discuss oppportunities to invest in or partner with the company.

William provides executive management oversight drawing on 25 years' of experience building healthcare companies.  Mr. Altman is a former McKinsey & Co. consultant, and co-founded two firms that grew to over $50M revenues, including one healthcare services company that grew to 500 employees. He has served on the boards of five growth companies, including a 7,000 employee NASDAQ listed company which increased its market capitalization from $0.5 billion to $1.5 billion during his tenure, when it was successfully sold.  Previously, Mr. Altman served as President & CEO of Kardia Therapeutics, a regenerative medicine company engaged in developing adult cardiac stem cells for use in heart failure therapy.  A native of New Ulm, Texas (pop. 500), Mr. Altman earned a B.S. degree in Electrical Engineering from Texas A&M University, an M.A. in Politics and Economics from Oxford University as a Rhodes Scholar, and an M.B.A. from Harvard Business School.

General management and commercial leader in medical devices, diagnostics, imaging capital equipment, and health care IT; US Surgical, Boston Scientific, Genzyme Genetics, Hologic, Oxford Immunotec, CRA Health.

Technology Director with over 20 years of experience in developing and testing network products and software. Responsible for delivering data center network products that are fully functional and available 24x7 to meet enterprise clients requirements. Ensure the upgrades, maintenance releases and security patches are delivered with exceptional quality.

Founder RDM Enterprises. CEO N8 Medical, Cora Therapeutics Nellix Inc, Millimed Holdings, President Endologix, COO Angio Dynamics, SVP Cook Medical, EVP Align Technologies.

Bio coming soon.

Bio coming soon.

Richard is an entrepreneur and investor with over 20 years of global commercial leadership experience in the healthcare industry.  He has expertise in building organizations to successfully execute GTM strategies with medical devices and digital health platforms. Richard previously worked at Abbott, Analyte Health, Honor, Velano Vascular and 3D Strategy Consulting, where he held roles in engineering, sales, marketing, and general management. He currently resides in San Francisco, CA.  Richard holds a BS in Applied Physics from Emory University and MSME in Bioengineering from Georgia Institute of Technology.

For nearly two decades, Rob has served in a variety of roles, leading and advising corporations, nonprofits, institutions of higher education, and state entities. Before being appointed CEO he served as president and chief operating officer at Vektor, where he led clinical, regulatory, engineering, and operations. Rob is a former partner at Vorys, Sater, Seymour and Pease LLP and a former Deputy Solicitor General for the State of Ohio. He had the privilege of clerking for the Honorable R. Guy Cole of the United States Court of Appeals for the Sixth Circuit. Rob earned his JD from Harvard Law School.

Jannis studied physics at FU and HU Berlin with exchanges to ETH Zurich, University of California Los Angeles, and CERN. During his PhD at ETH Zurich, he worked on the development of SAFIR, a small animal PET system with unprecedented temporal resolution. BPET (a SAFIR spin-off) started in 2017 with the grant of an ETH Pioneer Fellowship to Max and Jannis. Since then other awards have followed, e.g. VentureKick and Forbes Europe 30 under 30.

Founder, Executive Chairman & CEO of Lionheart Health, Inc. and Leonhardt Ventures LLC. Leonhardt Ventures LLC just celebrated their 40th Anniversary year in 2022. Over 700,000 patients have been treated with Leonhardt inventions.  Over 700 patent claims issued, pending, optioned or licensed to Howard Leonhardt for healthspan longevity extension, organ regeneration and healing. Inventions generate nearly $2 billion in revenues annually for their acquirers. Competing for $101 million XPRIZE for HealthSpan Extension. Founder of over 40 startups since 1982. Inventor of leading stent graft and percutaneous heart valve systems. Led team that completed first stem cell regeneration of a human heart without surgery in 2001. Working on developing a TOTAL BODY REGENERATION CHAMBER "Womb for Adults".  

Jose founded Bold Type to help companies solve hard technical problems. He has more than a decade of experience as a technical contributor and executive in various industries. These include the semiconductor industry, medical devices, consumer electronics, health and fitness, and the Internet of Things. Jose completed his PhD in electrical engineering and computer science at MIT with a minor in business administration from the Sloan School of Management. 

Bio coming soon.

Paul Molloy is Chief Executive Officer and a Director of the Company. Paul is an experienced CEO & General Manager with extensive global venture capital and private equity relationships. Paul has participated in two IPO’s, and exited three of his last four firms as CEO.  Paul has participated in exits at the Board level in several other MedTech firms in the last decade.  He is presently on the Board at ClearFlow, Inc. and Augustine Medical. He managed Teleflex’s largest division (Arrow Vascular) from 2011-2013 with a $700M P&L, six US and international manufacturing plants employing over 3,000 staff and a US sales organization of 100 reps. Paul was a CRNA in clinical practice, earned a diploma in Hospital Management from the Instituut Der Bedrijfswetenschappen in The Netherlands and holds an MBA from University of Chicago Booth School of Business. 

Bio coming soon.

Medtech executive with over 26 years of commercial experience. Formally Vice President and General Manager of Medtronic’s Interventional therapies business with expert knowledge of interventional spine procedures, biologics, and devices including Kyphoplasty and Vertebroplasty. His most recent role was Vice President Global reconstruction business at Zimmer Biomet.

• Michael Nagel joined Vomaris Innovations as President and CEO in February 2012.
• Mr. Nagel brings more than 30 years of sales and marketing experience in the medical device industry.
• Prior to Vomaris, Mr. Nagel served as Chief Commercial Officer at Neomend. He oversaw the commercial launch of a PMA device and guided rapid growth to over 1,200 hospitals. Neomend was acquired by C.R. Bard.
• Mr. Nagel also served as Co–Founder and Vice President of Worldwide Sales and Marketing at Vascular Solutions (VASC). He helped take Vascular Solutions from inception to IPO within 39 months and led the launch of a novel, biological vascular closure device in the interventional marketplace.
• He also served as Vice President of Sales and Marketing at Incisive Surgical.
• Mr. Nagel holds an MBA and BA from the University of St. Thomas.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Consultant surgeon and specialist in Advanced Laparoscopic , Bariatric & Cancer surgery, 20 Years of experience as surgeon, Successful Private Practice Medical entrepreneur & Inventor Of Peritoneoscope

Bio coming soon.

Bio coming soon.

Ir. Leo Smit graduated as a chemical engineer at the Delft University of Technology in 1986. He joined DSM in 1988. Following a 11 year career in R&D, he joined DSM’s Dyneema® Business Unit, where he became responsible for New Business Development.

Here he developed and launched DSM’s first implantable polymer material Dyneema Purity®, currently used worldwide and the golden standard for use in orthopedic reinforcement textiles. He served 4 years as Management Team member in the then newly installed Business Unit Biomedical Materials, responsible for passive biomaterials in orthopedic applications. Subsequently he acted 4 years as Director of Communications at the DSM Innovation Center, responsible for DSM’s (corporate) communications on science and innovation.

In 2016 Leo left DSM to found his own businesses. He started insightfully Innovate, advising and supporting companies both large and small in the field of medical devices. In 2019 Leo joined Hy2Care as CEO, responsible for the company & team development, strategy and financing of the company.

Personal quote:
“Hy2Care is a wonderful company to lead. We have a solid team of strong experts and above all great drive and commitment. Together we can bring forward the injectable hydrogel platform, delivering on the promise of better cartilage healing and much improved outcomes for patients all around the world!”

A medical device company President & CEO with broad general management, business development, marketing, engineering and operations experience providing vision, leadership and passion to products which impact the standard of patient care.

Bio coming soon,

The technical Co-Founder with over 10 years of experience in both small entrepreneurial and Fortune 500 companies in the medical device industry.

Mr. Jones is a Biodesign fellow and seasoned engineer who has successfully led and managed the technical teams for 11 different electrophysiology devices at Medtronic and Acutus Medical.

Passionate about driving change, Mr. Jones has dedicated his career to solving unmet clinical needs through the application of minimally invasive technologies. Now, Mr. Jones has joined forces with Dr. Morales to apply his experience from cardiac electrophysiology to the unmet needs in neurology - the next frontier. 

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

I have dedicated my career to study of the intersection of materials science and medicine with the goal of creating products to improve patients’ lives. At Arsenal Medical, I have led the development of our in situ forming foam platform. This exciting technology platform has commercial application in treating severely injured patients with abdominal hemorrhage through our ResQFoam product. I have managed ResQFoam from concept through development, securing $25M from the DOD (through DARPA and ARO). I was also the PI and inventor of an Arsenal technology that has enabled the scale up of electrospinning fibers, supported by $2.3M from NIST.

At 480 Biomedical, I was on the team that developed a novel bioresorbable scaffold technology to treat peripheral arterial disease. Through this novel composite design, we were able to achieve properties similar to metal stents, with a stent that is fully absorbable. I drove initial materials selection and oversaw preliminary drug delivery formulations. I also spearheaded the submission of a Fast-Track SBIR, resulting in a $1.7M award and initiating the development of our stent for pediatric pulmonary artery stenosis. Additionally, I oversaw our application for funding from Broadview Ventures, resulting in an additional $1.2M for the pediatric stent program.

My key areas of expertise:

--Grant Writing: Directed ideation and led the submission of government proposals resulting in over $27M of funding from DARPA and NIH

--Product Development: Led development and execution of our ResQFoam product including regulatory strategy and submissions, design control process and contract manufacturing, project timeline and budget, and establishment of a world-class advisory board

--Technical Management: Managed R&D group of up to 10 engineers & technicians

--Intellectual Property: Inventor on more than 25 pending or issued patents

--Publications: Authored 18 peer-reviewed scientific publications and 30+ presentations

Augie Lien is a successful serial entrepreneur in the medical devices field. He is most recently founder, Chairman, and CEO of Taiwan Aulisa Medical Device Technologies, Inc, which develops wireless, wearable FDA cleared vitals monitoring systems for at home use as well as systems integration at the healthcare institution level. By combining medical device sciences and information communication technologies, Aulisa’s proprietary innovations address unmet needs in the medical field and technological and operational trends within the healthcare industry.

Augie’s prior start-ups include Nellcor (IPO and subsequently acquired by Medtronic), which provides patient monitoring; Menlo Care (merged with Johnson and Johnson Medical), focusing on Hospital supplies; Gynecare (IPO and then acquire by Johnson and Johnson/Ethicon), addressing Gynecology Surgery needs; and EPI (acquired by Boston Scientific), which focuses on interventional Cardiology. These start-ups have all been acquired by multi-national companies or had an IPO in the US stock market. His fifth company, Cardiva Medical, is a successful interventional cardiology company which has been acquired by Haemonetics recently in February 2021.

Augie holds an MBA from the University of Santa Clara and an MS from Stanford University. He also graduated with an MA from National Chen Chi University and a BS from National Cheng Kung University, both in Taiwan.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Camilla has nine years’ biotech start-up experience as CEO and COO working exclusively on hydrogel-based medical devices. Originally a veterinary surgeon, she has run veterinary clinical trials and launched the veterinary arm of a biotech company. Following on from this she moved into the human biotech sector where she has been involved in all aspects of start-ups including, R&D, fundraising, regulatory, pre-clinical and clinical trials for medical devices.

Dr. Marsteller is a serial medical device entrepreneur and co-innovator of the RadianceTx technology. He previously founded Salutaris Medical Devices, Inc. – invested in by ophthalmic market leader HOYA (7741:Tokyo, Market Cap $21B, $4.5B in annual sales). He is a Medical Doctor (University of Arizona College of Medicine), and physicist (Yale University Graduate School). Dr. Marsteller has Investment Banking experience as an Analyst at Lehman Brothers, and subsequently Morgan Stanley.

B. Dusty Majumdar, PhD  is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years.  Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur.  He has authored several peer-reviewed scientific publications and holds multiple patents.

Bio coming soon.

Bio coming soon.

As the founder and CEO of Scalpel, I lead a passionate team of engineers and medics who build AI tools to enhance patient safety in the operating room.
Trained as a dentist, I have over eight years of interdisciplinary experience in healthcare and technology (Virtual Reality, Augmented Reality and Computer Vision). I previously built a startup (Open Simulation) to provide low-cost surgical simulation using Augmented Reality. In my doctoral research, I have designed and evaluated one of the first immersive virtual reality training tools for Oral and Maxillofacial Surgery.

Business leader and healthcare entrepreneur with over 25 years of experience in organizations of all sizes developing new technology and new markets in the U.S. and internationally with a particular focus on medical devices, digital health and diagnostics.

Particularly passionate about early stage ventures and intrapreneurial opportunities that require market analysis, needs assessment, product and business model discovery and definition, corporate strategic planning, and go-to-market execution.

James O’Reilly brings 20+ years of executive experience in technology company formation and growth. At Arrayus Technologies, he drives international investment and provides strategic vision.

Before leading Arrayus Technologies, James founded a successful consulting firm focusing on technology development, funding, and regulatory affairs in the medical device space. He is uniquely skilled as an enduring leader in the domain of high technology.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.